About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

A Phase 1 Open-Label, Dose-Escalation Study of Central Nervous System-Penetrant Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PRT3645, in Patients With Select Advanced or Metastatic Solid Tumors

Amita Patnaik, Mohamad A. Salkeni, Manish R. Patel, Atrayee Basu-Mallick, Dale Shepard, Christine Lihou, William Sun, Jennifer Xavier, Sri Sahasranaman, Neelesh Sharma, Erika Hamilton